Improving the safety of CAR-T-cell therapy: The risk and prevention of viral infection for patients with relapsed or refractory B-cell lymphoma undergoing CAR-T-cell therapy

被引：2
|
作者：
Qian, Hu [1 ,2 ]
Yang, Xingcheng [1 ,2 ]
Zhang, Tingting [3 ,4 ,5 ]
Zou, Ping [6 ]
Zhang, Yicheng [1 ,2 ]
Tian, Weiwei [4 ,5 ]
Mao, Zekai [1 ,2 ,8 ]
Wei, Jia [1 ,2 ,4 ,5 ,7 ]
机构：
[1] Huazhong Univ Sci & Technol, Tongji Hosp, Tongji Med Coll, Dept Hematol, Wuhan, Peoples R China
[2] Huazhong Univ Sci & Technol, Tongji Hosp, Tongji Med Coll, Immunotherapy Res Ctr Hematol Dis Hubei Prov, Wuhan, Peoples R China
[3] Third Hosp Shanxi Med Univ, Shanxi Bethune Hosp, Tongji Shanxi Hosp, Shanxi Acad Med Sci,Canc Ctr, Taiyuan, Peoples R China
[4] Third Hosp Shanxi Med Univ, Shanxi Bethune Hosp, Tongji Shanxi Hosp, Shanxi Acad Med Sci,Dept Hematol, Taiyuan, Peoples R China
[5] Shanxi Bethune Hosp, Shanxi Acad Med Sci, Sino German Joint Oncol Res Lab, Taiyuan, Shanxi, Peoples R China
[6] Huazhong Univ Sci & Technol, Union Hosp, Tongji Med Coll, Dept Hematol, Wuhan, Peoples R China
[7] Third Hosp Shanxi Med Univ, Shanxi Bethune Hosp, Tongji Shanxi Hosp, Shanxi Acad Med Sci,Dept Hematol, Taiyuan 030032, Shanxi, Peoples R China
[8] Huazhong Univ Sci & Technol, Tongji Hosp, Tongji Med Coll, Dept Hematol, 1095 Jiefang Ave, Wuhan 430030, Hubei, Peoples R China
来源：
AMERICAN JOURNAL OF HEMATOLOGY | 2024年 / 99卷 / 04期
基金：
中国国家自然科学基金;
关键词：
TIXAGEVIMAB-CILGAVIMAB; IMMUNE RECONSTITUTION; CLINICAL-ASPECTS; CHILDREN; RECOMMENDATIONS; MANAGEMENT; LEUKEMIA; DISEASE; MALIGNANCIES; ASSOCIATION;
D O I：
10.1002/ajh.27198
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
Chimeric antigen receptor (CAR) T-cell therapy, an innovative immunotherapeutic against relapsed/refractory B-cell lymphoma, faces challenges due to frequent viral infections. Despite this, a comprehensive review addressing risk assessment, surveillance, and treatment management is notably absent. This review elucidates immune response compromises during viral infections in CAR-T recipients, collates susceptibility risk factors, and deliberates on preventive strategies. In the post-pandemic era, marked by the Omicron variant, new and severe threats to CAR-T therapy emerge, necessitating exploration of preventive and treatment measures for COVID-19. Overall, the review provides recommendations for viral infection prophylaxis and management, enhancing CAR-T product safety and recipient survival. Risk factors and prevention recommendations for viral infections in CAR T-cell therapy.image
引用
收藏
页码：662 / 678
页数：17
相关论文
共 50 条
  • [21] Safety and clinical efficacy of BCMA CAR-T-cell therapy in multiple myeloma
    Gils Roex
    Marijke Timmers
    Kristien Wouters
    Diana Campillo-Davo
    Donovan Flumens
    Wilfried Schroyens
    Yiwei Chu
    Zwi N. Berneman
    Eva Lion
    Feifei Luo
    Sébastien Anguille
    [J]. Journal of Hematology & Oncology, 13
  • [22] Supportive Care for Patients with Lymphoma Undergoing CAR-T-cell Therapy: the Advanced Practice Provider's Perspective
    Granroth, Ginna
    Rosenthal, Allison
    McCallen, Maggie
    Coughlin, Christopher
    Benson, Hollie
    Palmer, Jeanne
    Castro, Januario E.
    Munoz, Javier
    [J]. CURRENT ONCOLOGY REPORTS, 2022, 24 (12) : 1863 - 1872
  • [23] Management of relapsed or refractory large B-cell lymphoma in patients ineligible for CAR-T cell therapy
    Perrone, Salvatore
    Lopedote, Paolo
    Levis, Mario
    Di Rocco, Alice
    Smith, Stephen Douglas
    [J]. EXPERT REVIEW OF HEMATOLOGY, 2022, 15 (03) : 215 - 232
  • [24] Supportive Care for Patients with Lymphoma Undergoing CAR-T-cell Therapy: the Advanced Practice Provider’s Perspective
    Ginna Granroth
    Allison Rosenthal
    Maggie McCallen
    Christopher Coughlin
    Hollie Benson
    Jeanne Palmer
    Januario E. Castro
    Javier Munoz
    [J]. Current Oncology Reports, 2022, 24 : 1863 - 1872
  • [25] The place of allogeneic stem cell transplantation in aggressive B-cell non-Hodgkin lymphoma in the era of CAR-T-cell therapy
    Castagna, Luca
    Bono, Roberto
    Tringali, Stefania
    Sapienza, Giuseppe
    Santoro, Alessandra
    Indovina, Alessandro
    Tarantino, Vittoria
    Di Noto, Laura
    Maggio, Aurelio
    Patti, Caterina
    [J]. FRONTIERS IN MEDICINE, 2022, 9
  • [26] CAR T-cell therapy in refractory large B-cell lymphoma
    Stirrups, Robert
    [J]. LANCET ONCOLOGY, 2018, 19 (01): : E19 - E19
  • [27] Neuropathological autopsy findings after CD19 CAR-T-cell therapy for diffuse large B-cell lymphoma
    Champion, Samantha
    Martinez-Lage, Maria
    [J]. LABORATORY INVESTIGATION, 2019, 99
  • [28] CAR-T-Cell Therapy for Patients with relapsed or refractory aggressive B-Cell-Lymphomas New Data prove Long-term Effectiveness
    Arnheim, Katharina
    [J]. ONCOLOGY RESEARCH AND TREATMENT, 2021, 44 (04) : 204 - 207
  • [29] Budget impact analysis of CAR-T-cell therapies for the inpatient treatment of adult patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL) in Germany
    Skalt, D.
    Berger, K.
    von Bergwelt-Baildon, M.
    Schmidt, C.
    Schoel, W.
    Subklewe, M.
    Weiglein, T.
    Dreyling, M.
    Moetl, B.
    [J]. ONCOLOGY RESEARCH AND TREATMENT, 2021, 44 : 281 - 281
  • [30] Could CAR-T-cell therapy offer hope to children with cancer?
    Dolgin, Elie
    [J]. NATURE, 2022, 612 (7941) : S50 - S52
12345